其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Finasteride CAS Registry Number: 98319-26-7 非那雄胺

CAS Name: (5a,17b)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
Additional Names: 17b-(N-tert-butylcarbamoyl)-4-aza-5a-androst-1-en-3-oneTrademarks: Chibro-Proscar (Chibret); F...
Literature References: Inhibitor of 5a-reductase, the enzyme which converts testosterone to the more potent androgen, 5a-dihydrotestosterone. Prepn: G. H. Rasmusson, G. F. Reynolds, EP 155096; eidem, US 4760071 (1985, 1988 both to Merck Co.); G. H. Rasmusson et al., J. Med. Chem. 29, 2298 (1986); A. Bhattacharya et al., J. Am. Chem. Soc. 110, 3318 (1988). HPLC determn in plasma and urine: J. R. Carlin et al., J. Chromatogr. 427, 79 (1988). Review of pharmacology and clinical uses: S. L. Sudduth, M. J. Koronkowski, Pharmacotherapy 13, 309-329 (1993). Clinical trials in benign prostatic hyperplasia: J. L. Tenover et al., Clin. Ther. 19, 243 (1997); J. D. McConnell et al., N. Engl. J. Med. 338, 557 (1998); in male pattern hair loss: K. D. Kaufman et al., J. Am. Acad. Dermatol. 39, 578 (1998).

Tenidap CAS Registry Number: 120210-48-2 替尼达普

CAS Name: (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide
Additional Names: 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-1H-indole-1-carboxamide; 5-chl...
Literature References: Inhibitor of 5-lipoxygenase and interleukin-1 (IL-1) activity. Prepn: S. B. Kadin, EP 156603; idem, US 4556672 (both 1985 to Pfizer). Effect on 5-lipoxygenase activity in vitro: K. Fogh et al., Arch. Dermatol. Res. 280, 430 (1988). Effect on IL-1 activity in patients with rheumatoid arthritis: B. McDonald et al., Arthritis Rheum. 31, Suppl., S52 (1988). Clinical evaluation: P. Katz et al., ibid. S52.

a -Methyl-m-tyrosine CAS Registry Number: 305-96-4 α-甲基-间酪氨酸

CAS Name: 3-Hydroxy-a-methylphenylalanine
Additional Names: a-methyl-3-(m-hydroxyphenyl)alanine; a-MMT
Percent Composition: C 61.52%, H 6.71%, N 7.17%, O 24.59%
Literature References: Inhibitor of catecholamine synthesis. Prepn of DL-form: Stein et al., J. Am. Chem. Soc. 77, 700 (1955); Pfister, Stein, US 2868818 (1959 to Merck Co.).

Pemirolast CAS Registry Number: 69372-19-6 吡嘧司特

CAS Name: 9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
Percent Composition: C 52.63%, H 3.53%, N 36.83%, O 7.01%
Literature References: Inhibitor of chemical mediator release from tissue mast cells. Prepn: P. F. Juby, US 4122274 (1978 to Bristol-Myers). LC determn in plasma: H. Cheng et al., J. Pharm. Sci. 76, 918 (1987). Immunopharmacology and mechanism of action studies: Y. Yanagihara et al., Jpn. J. Pharmacol. 48, 91, 103 (1988). Clinical evaluation in allergic rhinitis: D. G. Tinkelman, R. B. Berkowitz, Ann. Allergy 66, 162 (1991).

Fosmidomycin CAS Registry Number: 66508-53-0 膦胺霉素

CAS Name: [3-(Formylhydroxyamino)propyl]phosphonic acid
Percent Composition: C 26.24%, H 5.50%, N 7.65%, O 43.69%, P 16.92%
Literature References: Inhibitor of microbial nonmevalonate isoprenoid biosynthesis. Prepn: T. Kamiya et al., US 4206156 (1980 to Fujisawa); K. Hemmi et al., Chem. Pharm. Bull. 29, 646 (1981); eidem, ibid. 30, 111 (1982). Synthesis: E. Ohler, S. Kanzler, Synthesis 1995, 539 (1995). CE determn in serum and urine: S. Bronner et al., J. Chromatogr. B 806, 255 (2004). Mode of action: T. Kuzuyama et al., Tetrahedron Lett. 39, 7913 (1998); H. Jomaa et al., Science 285, 1573 (1999). Pharmacokinetics: T. Murakawa et al., Antimicrob. Agents Chemother. 21, 224 (1982); H.-P. Kuemmerle et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 23, 515, 521 (1985). Clinical evaluation in malaria: M. A. Missinou et al., Lancet 360, 1941 (2002); in combination with clindamycin: S. Borrmann et al., J. Infect. Dis. 189, 901 (2004); idem et al., ibid. 190, 1534 (2004). Interaction with other antimalarial drugs and synergy with clindamycin: J. Wiesner et al., Antimicrob. Agents Chemother. 46, 2889 (2002). Review: idem et al., Parasitol. Res. 90, S71-S76 (2003).

Liarozole CAS Registry Number: 115575-11-6 6-((3-氯苯基)(1H-咪唑-1-基)甲基)-1H-苯并[d]咪唑

CAS Name: 5-[(3-Chlorophenyl)-1H-imidazol-1-ylmethyl]-1H-benzimidazole
Additional Names: (±)-5-(m-chloro-a-imidazol-1-ylbenzyl)benzimidazole
Percent Composition: C 66.13%, H 4.24%, Cl 1...
Literature References: Inhibits cytochrome P450-dependent enzymes involved in steroid biosynthesis and retinoic acid catabolism. Prepn: A. H. M. Raeymaekers et al., EP 260744; eidem, US 4859684 (1988, 1989 both to Janssen). In vivo antitumor activity: R. Van Ginckel et al., Prostate 16, 313 (1990). Pharmacology and effect on steroid synthesis: J. Bruynseels et al., ibid., 345; and effect on retinoic acid: R. De Coster et al., J. Steroid Biochem. Mol. Biol. 43, 197 (1992). Clinical evaluation in prostate cancer: C. Mahler et al., Cancer 71, 1068 (1993); in psoriasis: P. Dockx et al., Br. J. Dermatol. 133, 426 (1995); in combination therapy for malignant brain tumors: M. E. Westarp et al., Onkologie 16, 22 (1993).

NPPB CAS Registry Number: 107254-86-4 5-硝基-2-(3-苯丙胺)苯甲酸

CAS Name: 5-Nitro-2-[(3-phenylpropyl)amino]benzoic acidPercent Composition: C 63.99%, H 5.37%, N 9.33%, O 21.31%
Literature References: Inhibits efflux of ion channels; specificity is cell type dependent. Prepn: H. C. Englert et al., DE 3528048; eidem, US 4994493 (1987, 1991 both to Hoechst). Synthesis and characterization as potassium channel blocker: K. R. Giles et al., Bioorg. Med. Chem. Lett. 13, 293 (2003). Blocking kinetics of chloride channels: J. Dreinhöfer et al., Biochim. Biophys. Acta 946, 135 (1988). Effect on chloride ion transport: B. R. Branchini et al., Biochem. Biophys. Res. Commun. 176, 459 (1991); eidem, Arch. Biochem. Biophys. 318, 221 (1995); J.-A. Kim et al., Biochem. Biophys. Res. Commun. 309, 291 (2003).

Famoxadone CAS Registry Number: 131807-57-3 恶唑酮菌

CAS Name: 5-Methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-2,4-oxazolidinedione
Additional Names: 3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dioneTrademarks: Famoxate (DuPont)
Pe...
Literature References: Inhibits electron transport via blockage of ubiquinol:cytochrome c oxidoreductase. Prepd not claimed: D. Geffken, D. R. Rayner, US 4957933 (1990 to DuPont). Biological activity and field trials: M. M. Joshi, J. A. Sternberg, Proc. Br. Crop Prot. Conf. - Pests Dis. 1996, 21. Mode of action: D. B. Jordan et al., Pestic. Sci. 55, 105 (1999). Environmental fate: K. M. Jernberg, P. W. Lee, ibid. 587. Metabolic fate in plants and animals: P. W. Lee et al., ibid. 589. Review of synthesis and structure-activity relationship: J. A. Sternberg et al., ACS Symp. Ser. 686, 216-227 (1998).

Amlexanox CAS Registry Number: 68302-57-8 氨来呫诺

CAS Name: 2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid
Additional Names: 2-amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid; 2-am...
Literature References: Inhibits release of allergic mediators from mast cells. Prepn: A. Nohara et al., BE 864647; US 4143042 (1978, 1979 both to Takeda); eidem, J. Med. Chem. 28, 559 (1985). Mode of action studies: T. Saijo et al., Int. Arch. Allergy Appl. Immunol. 79, 231 (1986); H. Makino et al., ibid. 82, 66 (1987). Pharmacodynamics: G. Rankov et al., Ophthalmic Res. 22, 359 (1990). Clinical trial in aphthous ulcers: R. O. Greer, Jr. et al., J. Oral Maxillofac. Surg. 51, 243 (1993).

Fertilysin CAS Registry Number: 1477-57-2 N,N'-八亚甲基双二氯乙酰胺

CAS Name: N,N'-1,8-Octanediylbis[2,2-dichloroacetamide]
Additional Names: N,N'-octamethylenebis(2,2-dichloroacetamide); N,N'-bis(dichloroacetyl)-1,8-octamethylenediaminePercent Composition: C 3...
Literature References: Inhibits spermatogenesis without affecting production of gonadotropins in male laboratory animals. Prepn and biological activity: Surrey, Mayer, J. Med. Pharm. Chem. 3, 419 (1961); Surrey, US 3143566 (1964 to Sterling Drug). Assessment of antifertility activity in rats: S. Nag, J. J. Ghosh, J. Steroid Biochem. 11(1B), 681 (1979). Teratological study: P. Taleporos et al., Teratology 18, 5 (1978). Toxicology study: F. Coulston et al., Toxicol. Appl. Pharmacol. 2, 715 (1960).